Gleave ME - Search Results

1

Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.

Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y; Canary Prostate Active Surveillance Study Investigators. Lin DW, et al. Among authors: gleave me. Eur Urol. 2017 Sep;72(3):448-454. doi: 10.1016/j.eururo.2016.11.017. Epub 2016 Nov 23. Eur Urol. 2017. PMID: 27889277 Free PMC article. Clinical Trial.

2

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1996 Jan;155(1):213-9. J Urol. 1996. PMID: 7490838 Clinical Trial.

3

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Goldenberg SL, et al. Among authors: gleave me. Urology. 1995 May;45(5):839-44; discussion 844-5. doi: 10.1016/s0090-4295(99)80092-2. Urology. 1995. PMID: 7538246 Clinical Trial.

4

Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.

Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, Goldenberg SL, Sullivan LD. Gleave ME, et al. Urology. 1996 May;47(5):708-12. doi: 10.1016/s0090-4295(96)80016-1. Urology. 1996. PMID: 8650870

5

Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD. Goldenberg SL, et al. Among authors: gleave me. Urology. 1996 Jun;47(6):882-4. doi: 10.1016/S0090-4295(96)00048-9. Urology. 1996. PMID: 8677581 Clinical Trial.

6

Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.

Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD. Gleave ME, et al. J Urol. 1997 May;157(5):1727-30. J Urol. 1997. PMID: 9112514

7

Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Gleave M, Bruchovsky N, Goldenberg SL, Rennie P. Gleave M, et al. Eur Urol. 1998;34 Suppl 3:37-41. doi: 10.1159/000052297. Eur Urol. 1998. PMID: 9854195 Review.

8

Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.

Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Gleave ME, et al. Urology. 2000 Aug 1;56(2):289-94. doi: 10.1016/s0090-4295(00)00627-0. Urology. 2000. PMID: 10925096

9

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.

Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH, Jewett M, Kassabian V, Chetner M, Dupont C, Van Rensselaer S; Canadian Uro-Oncology Group. Gleave ME, et al. J Urol. 2001 Aug;166(2):500-6; discussion 506-7. J Urol. 2001. PMID: 11458055 Clinical Trial.

10

Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.

Pether M, Goldenberg SL, Bhagirath K, Gleave M. Pether M, et al. Can J Urol. 2003 Apr;10(2):1809-14. Can J Urol. 2003. PMID: 12773232

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

666 results

Search Page

Filters